Five Star Equities Issues New Research Reports on ACUR, GILD, HOLX and PRANadmin
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) shares declined 0.59 percent to close at $1.68 a share Monday. The stock traded between $1.66 and $1.85 on volume 1.34 million shares traded. The company announced that the FDA has agreed to review “whether the results of Study 301 are acceptable for submission in a New Drug Application (NDA).” Shares of Acura Pharmaceuticals have fallen approximately 24.0 percent year-to-date.
Get more information on Acura Pharmaceuticals and free access to the in-depth equity report at:
Gilead Sciences, Inc. (NASDAQ: GILD) shares gained 1.62 percent to close at $75.19 a share Monday. The stock traded between $74.23 and $76.11 on volume 17.25 million shares traded. The company recently announced that the FDA has approved Sovaldi for the treatment of chronic hepatitis C. Shares of Gilead Sciences have gained approximately 100.0 percent year-to-date.
Get more information on Gilead Sciences and free access to the in-depth equity report at:
Hologic, Inc. (NASDAQ: HOLX) shares declined 0.76 percent to close at $22.12 a share Monday. The stock traded between $21.74 and $22.80 on volume 11.18 million shares traded. The company announced that Stephen P. MacMillan has been named President and Chief Executive Office. Shares of Hologic have gained approximately 10.0 percent year-to-date.
Get more information on Hologic free access to the in-depth equity report at:
Prana Biotechnology Limited (NASDAQ: PRAN) shares surged 16.46 percent to close at $6.65 a share Monday. The stock traded between $6.12 and $7.48 on volume of 5.33 million shares traded. The company announced the completion of the treatment phase of its IMAGINE Alzheimer’s Disease clinical trial. Shares of Prana Biotechnology have gained nearly 200.0 percent year-to-date.
Get more information on Prana Biotechnology and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Posted: December 10th, 2013 under ACCESSWIRE.